Phase I clinical trial - Hématologie Lymphome non Hodgkinien
LOXO-BCL-20001
Hématologie Lymphome non Hodgkinien
Essai clinique fermé
Public cible
Adulte
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies.
Description de l'essai
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Liens utiles
FREDERIQUE KUHNOWSKI
Investigateur principal